TX-FORTERRO
17.2.2021 10:02:16 CET | Business Wire | Press release
Forterro , a group of companies that deliver enterprise resource planning (ERP) software to small- and medium-sized businesses, today announced the appointment of two new executives to lead the company into a new phase of growth in its core market, Europe.
Dean Forbes, a longtime, U.K.-based software executive who was most recently the president of The Access Group, was named Forterro’s chief executive. Paul Smolinski, the former chief financial officer of HR and payroll software firm CoreHR, was named CFO. The two U.K.-based leaders have been tapped to continue Forterro’s growth strategy in Europe, working with the company’s strategic leadership teams across the group’s primary business units in France, Germany, Poland, Sweden, and Switzerland.
Forbes joins Forterro after an extensive career in executive and senior leadership roles for a number of international software companies. Most recently he led the growth and expansion of CoreHR, a UK HCM software provider, across Europe. CoreHR was acquired by The Access Group, where Forbes subsequently served as president and executive board member. Prior to CoreHR, Forbes was CEO of Paris-headquartered SaaS software company KDS, where he led the successful growth and international expansion of the firm, leading to its acquisition by American Express. Earlier in his career, Forbes held senior leadership roles at Philadelphia HQ’d Primavera Systems and, subsequently, Oracle where he was global vice president for sales and marketing for the PPM Division. Forbes brings this wealth of experience to Forterro and its acquired companies, which include abas Software (Germany); BPSC (Poland); Clip Industrie, Silog and Sylob (France); Jeeves and Infocube (Sweden); and ProConcept (Switzerland). Forterro is backed by global, technology-focused investment firm Battery Ventures.
“I am thrilled to become part of such a strong group of ERP companies, who are all successfully operating in one of the strongest, most steadily growing markets in enterprise software,” Forbes said. “The cornerstone of our ongoing success will be to continue investing in the market leadership positions of local and niche ERP software businesses throughout Europe. I am excited about leading the next stage of the Forterro journey as we look to continue to grow the business aggressively, both organically and through further acquisitions.”
“Bringing in new, Europe-based leadership is part of the natural evolution of Forterro,” said Dave Tabors, a Forterro board member and Battery Ventures private equity partner. “Former CEO Jeff Tognoni, former COO Scott Malia, and the rest of the U.S.-based Forterro leadership team have done an outstanding job of growing the business by evaluating, acquiring, and operating ERP companies. To push Forterro into its next stage of development, however, it is time to cultivate leadership talent in closer proximity to our business unit operations. We are very excited to work with Dean as he prepares Forterro for its next stage of growth.”
“We have spent the last several years working closely with our counterparts in Europe to build sustainable growth strategies and unique operating approaches for each business unit and product market,” added Jeff Tognoni, who is stepping down after leading Forterro and growing revenue more than seven-fold since the initial acquisition of Jeeves Information Systems in 2012. “The strength of our local teams and their businesses lets me know that part of our job is done, and that Forterro is ready for new challenges and continued success under the leadership of Dean and Paul.”
ABOUT FORTERRO
Forterro is a group of companies that deliver ERP software to SMEs in specialized geographical or vertical markets. Backed by the investment of Battery Ventures , Forterro operates business units in Sweden, Switzerland, France, Poland, and Germany, as well as regional office locations and research and development centers around the world. Through its ever-growing ecosystem of IP and capital, Forterro collaborates with local management teams to strengthen the solution offerings and operational performance of its portfolio companies. For more information, visit www.forterro.com .
ABOUT BATTERY VENTURES
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom